Pfizer (Comirnaty) ≥12 years formulation – generic name tozinameran or BNT162b2
Category |
Detail |
---|---|
Sponsor |
Pfizer Australia Pty Ltd |
Approved age for use |
≥12 years |
Presentation |
Multidose vial without preservative. Each vial contains 6 doses in 0.45 mL. Requires dilution with 1.8 mL of sterile 0.9% NaCl without preservative into each multidose vial |
Cap colour |
Purple |
Volume/strength |
0.3 mL (30 µg) per dose |
Schedule |
2 doses, 3 to 8 weeks apart |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.3 mL dose contains 30 µg mRNA encoding the SARS-CoV-2 spike glycoprotein |
Excipients |
|
Pfizer (Comirnaty) 5 to 11 years formulation – generic name tozinameran or BNT162b2
Category |
Detail |
---|---|
Sponsor |
Pfizer Australia Pty Ltd |
Approved age for use |
5 to <12 years |
Presentation |
Tris/sucrose presentation. Multidose vial containing 10 doses in 1.3 mL. Requires dilution with 1.3 mL of sterile 0.9% NaCl without preservative into each multidose vial |
Cap colour |
Orange |
Volume/strength |
0.2 mL (10 µg) per dose |
Schedule |
2 doses, 8 weeks apart |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.2 mL dose contains 10 µg mRNA encoding the SARS-CoV-2 spike glycoprotein |
Excipients |
|
Pfizer (Comirnaty) 6 months to 4 years formulation – generic name tozinameran or BNT162b2
Category | Detail |
---|---|
Sponsor |
Pfizer Australia Pty Ltd |
Approved age for use |
6 months to <5 years |
Presentation |
Tris/sucrose presentation. Multidose vial containing 10 doses in 0.4 mL. Requires dilution with 2.2 mL of sterile 0.9% NaCl without preservative into each multidose vial |
Cap colour |
Maroon |
Volume/strength |
0.2 mL (3 µg) per dose |
Schedule |
3 doses, each dose 8 weeks apart |
Administration route |
For infants aged 6 to 12 months: Intramuscular injection into vastus lateralis muscle of the anterolateral thigh For children aged ≥12 months: Intramuscular injection into deltoid muscle (or into the vastus lateralis muscle of the anterolateral thigh) |
Ingredients |
Each 0.2 mL dose contains 3 µg mRNA encoding the SARS-CoV-2 spike glycoprotein |
Excipients |
|
Pfizer (Comirnaty) bivalent original/Omicron BA.1 ≥18 years formulation – generic name tozinameran or BNT162b2 (OMI) BA.1
Category |
Detail |
---|---|
Sponsor |
Pfizer Australia Pty Ltd |
Approved age for use |
≥18 years |
Presentation |
Multidose vial containing 6 doses of 0.3 mL. Does not require dilution |
Cap colour |
Grey |
Volume/strength |
0.3 mL (30 µg) per dose |
Schedule |
1 dose |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.3 mL dose contains 15 µg of tozinameran and 15 µg of riltozinameran |
Excipients |
|
Moderna (Spikevax) original ≥ 6 years formulation – generic name elasomeran or mRNA-1273
Category |
Detail |
---|---|
Sponsor |
Moderna Australia Pty Ltd |
Approved age for use |
≥6 years |
Presentation |
5 mL multidose vial without preservative |
Cap colour |
Red |
Volume/strength |
For children aged 6 to 11 years: 0.25 mL per dose For people aged ≥12 years as a primary course: 0.5 mL per dose For people aged ≥18 years as a booster: 0.25 mL per dose |
Schedule |
For children aged 6 to 11 years: 2 doses, 8 weeks apart For people aged ≥12 years: 2 doses, 4 to 8 weeks apart |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.5 mL dose contains 100 μg mRNA encoding the SARS-CoV-2 spike glycoprotein (50 ug in each 0.25 mL dose) |
Excipients |
|
Moderna (Spikevax) 6 months to 5 years formulation – generic name elasomeran or mRNA-1273
Category |
Detail |
---|---|
Sponsor |
Moderna Australia Pty Ltd |
Approved age for use |
6 months to 5 years |
Presentation |
2.5 mL multidose vial without preservative |
Cap colour |
Blue. Note that the Moderna bivalent vaccine also has a blue cap. To minimise the risk of administration errors, providers should preferably prepare and store doses of these vaccines separately. Doses withdrawn in advance of administration should be clearly labelled. |
Volume/strength |
0.25 mL per dose |
Schedule |
2 doses, 8 weeks apart |
Administration route |
For infants aged <12 months: Intramuscular injection into vastus lateralis muscle of the anterolateral thigh For children aged ≥12 months: Intramuscular injection into deltoid muscle (or into the vastus lateralis muscle of the anterolateral thigh) |
Ingredients |
Each 0.25 mL dose contains 25 μg mRNA encoding the SARS-CoV-2 spike glycoprotein |
Excipients |
|
Moderna (Spikevax) bivalent 18 years and older – generic name elasomeran/imelasomeran or mRNA-1273.214
Category |
Detail |
---|---|
Sponsor |
Moderna Australia Pty Ltd |
Approved age for use |
≥18 years |
Presentation |
2.5 mL multidose vial without preservative |
Cap colour |
Blue. Note that the Moderna 6 months to 5 years formulation also has a blue cap. To minimise the risk of administration errors, providers should preferably prepare and store doses of these vaccines separately. Doses withdrawn in advance of administration should be clearly labelled. |
Volume/strength |
0.5 mL per dose |
Schedule |
1 dose, 3 months after last dose |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.5 mL dose contains 25 μg elasomeran (ancestral SARS-CoV-2) and 25 μg imlasomeran (Omicron BA.1 subvariant) |
Excipients |
|
AstraZeneca (Vaxzevria) – generic name ChAdOx1s
Category |
Detail |
---|---|
Sponsor |
AstraZeneca Pty Ltd |
Approved age for use |
≥18 years |
Presentation |
Multidose vial without preservative, each vial containing either 8 doses in 4 mL or 10 doses in 5 mL |
Volume/strength |
0.5 mL per dose |
Schedule |
2 doses, 4 to 12 weeks apart |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.5 mL dose contains 5 x 1010 viral particles of ChAdOx1-S, a recombinant, non-replicating chimpanzee adenovirus vector encoding the SARS-CoV-2 spike glycoprotein |
Excipients |
|
Novavax (Nuvaxovid) – generic name NVX-CoV2373
Category |
Detail |
---|---|
Sponsor |
Biocelect Pty Ltd on behalf of Novavax Ltd |
Approved age for use |
≥12 years |
Presentation |
Multidose vial without preservative, each vial containing 10 doses in 5 mL |
Volume/strength |
5 µg antigen, 50 µg Matrix-M |
Schedule |
2 doses, 3 to 8 weeks apart |
Administration route |
Intramuscular injection into deltoid muscle |
Ingredients |
Each 0.5 mL dose contains 5 µg of SARS-CoV-2 spike protein, adjuvanted with Matrix-M. Adjuvant Matrix-M contains Fraction-A (42.5 µg) and Fraction-C (7.5 µg) of Quillaja saponaria Molina extract |
Excipients |
|